AVIR (Atea Pharmaceuticals) Dividend Payout Ratio : 0.00 (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Atea Pharmaceuticals Dividend Payout Ratio?

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Atea Pharmaceuticals's Dividend Payout Ratio for the months ended in Dec. 2024 was 0.00.

The historical rank and industry rank for Atea Pharmaceuticals's Dividend Payout Ratio or its related term are showing as below:

AVIR's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.45
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2025-03-17), the Dividend Yield % of Atea Pharmaceuticals is 0.00%.

Atea Pharmaceuticals's Dividends per Share for the months ended in Dec. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

Atea Pharmaceuticals Dividend Payout Ratio Historical Data

The historical data trend for Atea Pharmaceuticals's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atea Pharmaceuticals Dividend Payout Ratio Chart

Atea Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dividend Payout Ratio

Get a 7-Day Free Trial

Atea Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Dividend Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Atea Pharmaceuticals's Dividend Payout Ratio

For the Biotechnology subindustry, Atea Pharmaceuticals's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atea Pharmaceuticals's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atea Pharmaceuticals's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Atea Pharmaceuticals's Dividend Payout Ratio falls into.

Atea Pharmaceuticals Dividend Payout Ratio Calculation

Atea Pharmaceuticals's Dividend Payout Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2024 )	/	EPS without NRI (A: Dec. 2024 )
	=	0	/	-2
	=	N/A

Atea Pharmaceuticals's Dividend Payout Ratio for the quarter that ended in Dec. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2024 )	/	EPS without NRI (Q: Dec. 2024 )
	=	0	/	-0.4
	=	N/A

Atea Pharmaceuticals (NAS:AVIR) Dividend Payout Ratio Explanation

In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Atea Pharmaceuticals Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Atea Pharmaceuticals's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Atea Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atea Pharmaceuticals Inc (NAS:AVIR) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

225 Franklin Street, Suite 2100, Boston, MA, USA, 02110

Website

https://www.ateapharma.com

Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).

Executives

Franklin M Berger	director	1000 MARINA BLVD, STE 200, BRISBANE CA 94005
Jean-pierre Sommadossi	director, 10 percent owner, officer: President, CEO, and Chairman	125 SUMMER STREET, 16TH FLOOR, BOSTON MA 02110
Bruce Polsky	director	C/O VISION-SCIENCES, INC., 40 RAMLAND ROAD, ORANGEBURG NY 10962
Andrea Corcoran	officer: See Remarks	125 SUMMER STREET, 16TH FLOOR, BOSTON MA 02110
Janet Mj Hammond	officer: Chief Development Officer	C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
John Vavricka	officer: Chief Commercial Officer	C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Maria Arantxa Horga	officer: Acting Chief Medical Officer	C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Wayne Foster	officer: See Remarks	125 SUMMER STREET, 16TH FLOOR, BOSTON MA 02110
Polly A. Murphy	director	C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Jerome M. Adams	director	C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Hack Andrew A. F.	director	300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142
Rock Springs Capital Master Fund Lp	10 percent owner	190 ELGIN AVENUE, GEORGE TOWN E9 KY1 9001
Cormorant Global Healthcare Master Fund, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund I, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Rock Springs Capital Llc	10 percent owner	650 SOUTH EXETER STREET, SUITE 1070, BALTIMORE MD 21202